COX-2 overexpression in canine tumors: Potential therapeutic targets in oncology

Histology and Histopathology

Volumn 20, Issue 4, 2005, Pages 1309-1312

  Spugnini, Enrico P ^a   Porrello, A ^a   Citro, G ^a   Baldi, A ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Canine tumors; Chemotherapy; COX 2

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOENZYME; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

CARCINOGENESIS; COLORECTAL CANCER; DOG; DOG DISEASE; DRUG TARGETING; ENZYME INDUCTION; FOWL; GASTROINTESTINAL TRACT; GENE OVEREXPRESSION; INFLAMMATION; LUNG NON SMALL CELL CANCER; MAMMAL; MESOTHELIOMA; NONHUMAN; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOG DISEASES; DOGS; NEOPLASMS;

AVES; CANIS FAMILIARIS; MAMMALIA;

EID: 27144435529     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Ando G.A. and Lombardino J.G. (11983). Piroxicam: a literature review of new results from laboratory and clinical studies. Eur. J. Rheumatol. Inflamm. 6, 3-23.
2. Baldi A., Santini D., Vasaturo F., Santini M., Vicidomini G., Di Marino M.P., Esposito V., Groeger A.M., Liuzzi G., Vincenzi B., Tonini G., Piccoli M., Baldi F. and Scarpa S. (2004). Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 59, 428-433.
3. Beam S.L., Rassnick K. M., Moore A.S. and McDonough S.P. (2003). An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Vet. Pathol. 40, 496-500.
4. Brock T.G., McNish R.W. and Peters-Golden M. (1999). Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J. Biol. Chem. 274, 11660-11666.
5. Castelao J.E., Yuan J.M., Gago-Dominguez M., Yu M.C. and Ross R.K. (2000). Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. Br. J. Cancer 82, 1364-1369.
6. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Sha J.P., Edelstein D., Soslow R.A., Koki A.T., Woemer B.M., Mansferrer J.L. and Dannenberg A.J. (1999). Cycloxoygenase-2 expression is up-regulated in squamous cell carcinoma of head and neck. Cancer Res. 59, 991-994.
7. Dore M., Lanthier I. and Sirois J. (2003). Cyclooxygenase-2 expression in canine mammary tumors. Vet. Pathol. 40, 207-212.
8. Garcia-Rodriguez L.A. and Huerta-Alvarez C. (2001). Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Epidemiology 12, 88-93.
9. Hahn K.A., Bravo L., Adams W.H. and Frazier D.L. (1994). Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo 8, 133-143.
10. Half E., Tang XM., Gwyn K., Sahin A., Wathen K. and Sinicrope F.A. (2002). Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 62, 1676-1681.
11. Hao X., Bishop A.E., Wallace M., Wang H., Willcocks T.C., Maclouf J., Polak J.M., Knight S. and Talbot I.C. (1999). Early expression of cyclooxyenase-2 during sporadic colorectal carcinogenesis. J. Pathol. 187, 295-301.
12. Henry C.J., McCaw D., Turnquist S.E., Tyler J.W., Bravo L., Sheafor S., Straw R.C., Dernell W.S., Madewell B.R., Jorgensen L., Scott M.A., Higginbotham M.L. and Chun R. (2003). Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin. Cancer Res. 9, 906-911.
13. Khan K.N., Venturini C.M., Bunch R.T., Brassard J.A., Koki A.T., Morris D.L., Trump B.F., Maziars J.J. and Alden C.L. (1998). Interspecies differences in renal localization of cyclooxygenase isoforms; implication in nonsteroidal anti-inflammatory drug-related nephrotoxicity. Toxicol. Pathol. 5, 612-620.
14. Khan K.N., Knapp D.W., Denicola D.B. and Harris R.K. (2000). Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am. J. Vet. Res. 61, 478-481.
15. Khan K.N., Stanfield K.M., Trajkovic D. and Knapp D.W. (2001). Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet. Pathol. 38, 116-119.
16. Kleiter M., Malarkey D.E., Ruslander D.E. and Thrall D.E. (2004). Expression of cyclooxygenase-2 in canine epithelial nasal tumors. Vet. Radiol. Ultrasound 45, 255-260.
17. Knapp D.W. and Waters D.J. (1997). Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol. Med. Today 3, 8-11.
18. Knapp D.W., Richardson R.C., Bottoms G.D., Teclaw R. and Chan T.C. (1992). Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother. Pharmacol. 29, 214-218.
19. Knapp D.W., Richardson R.C., Chan T.C., Bottoms G.D., Widmer W.R., De Nicola D.B., Teclaw R., Bonney P.L. and Kuczek T. (1994). Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J. Am. Vet. Med. Assoc. 8, 273-278
20. Knapp D.W., Glickman N.W., Widmer W.R., De Nicola D.B., Adams L.G., Kuczek T., Bonney P.L., De Gortari A.E., Han C. and Glickman L.T. (2000a). Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother. Pharmacol. 46, 221-226.
21. Knapp D.W., Glickman N.W., De Nicola D.B., Bonney P.L., Lin T. and Glickman L.T. (2000b). Naturally-occurring canine transitional cell carcinoma of the urinary bladder. Urol. Oncol. 5, 47-59.
22. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Mansferrer J.L., Subbaramaiah K. and Dannenberg A.J. (2001). Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7, 429-434.
23. Mestre J.R., Subbaramaiah K., Sacks P.G., Schantz S.P., Tanabe T., Inoue H. and Danneberg A.J. (1997). Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res. 57, 2890-2895.
24. Mac Ewen E.G. (1990). Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Met. Rev. 9, 125-136.
25. McEntee M.F., Cates J.M. and Neilsen N. (2002). Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet. Pathol. 39, 428-436.
26. Mohammed S.I., Knapp D.W., Bostwick D.G., Foster R.S., Khan K.N., Masferrer J.L., Woerner B.M., Snyder P.W. and Koki A.T. (1999). Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 59, 5647-5650.
27. Mohammed S.I., Coffman K., Glickman N.W., Hayek M.G., Waters D.J., Schlittler D., De Nicola D.B. and Knapp D.W. (2001). Prostaglandin E2 concentrations in naturally occurring canine cancer. Prostaglandins Leukot. Essent. Fatty Acids 64, 1-4.
28. Mohammed S.I., Bennett P.F., Craig B.A., Glickman N.W., Mutsaers A.J., Snyder P.W., Widmer W.R., De Gortari A.E., Bonney P.L. and Knapp D.W. (2002). Effects of the cylooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 62, 356-358.
29. Mullins M.N., Lana S.E., Dernell W.S., Ogilvie G.K., Withrow S.J. and Ehrhart E.J. (2004). Cyclooxygenase-2 expression in canine appendicular osteosarcoma. J. Vet. Intern. Med. 18, 859-865.
30. Nathan C.A., Leskov I.L., Lin M., Abreo F.W., Shi R., Hartman G.H. and Glass J. (2001). COX-2 expression in dysplasia of the head and neck. Cancer 92, 1888-1895.
31. Nigro N.D., Bull A.W. and Boyd M.E. (1986). Inhibition of intestinal carcinogenesis in rats: effects of difluoromethylornithine with piroxicam or fish oil. J. Natl. Cancer Inst. 77, 1309-1313.
32. Ostrom R.S., Gregorian C., Drenan R.M., Gabot K., Rana B.K. and Insel P.A. (2001). Key role for constitutive cyclooxygenase-2 of MDCK cells in basal signaling and response to released ATP. Am. J. Physiol. Cell. Physiol. 281, C524-C531.
33. Parhar R.S. and Lala P.K. (1988). Prostaglandin E2 mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J. Leuk. Biol. 44, 474-484.
34. Pestili de Almeida E.M., Piche C., Sirois J. and Dore M. (2001). Expression of cyco-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J. Histochem. Cytochem. 49, 867-875.
35. Pollard M. and Luckert P.H. (1989). Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res. 49, 6471-6473.
36. Pollard M., Luckert P.H. and Schmidt M.A. (1983). The suppressive effect of piroxicam on autochtonous intestinal tumors in the rat. Cancer Lett. 25, 57-61.
37. Porrello A., Cardelli P. and Spugnini E.P. (2004). Pet models in cancer research: general principles. J. Exp. Clin. Cancer Res. 23, 181-193.
38. Reddy B.S., Maruyama H. and Kelloff G. (1987). Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 47, 5340-5346.
39. Reddy B.S. and Rao C.V. (2002). Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J. Environ. Pathol. Toxicol. Oncol. 21, 155-164.
40. Ristimaki A., Honkanen N., Jankala H., Sipponen P. and Harkonen M. (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57, 1276-1280.
41. Schreinemachers D.M. and Everson R.B. (1994). Aspirin use and lung, colon and breast cancer in a prospective study. Epidemiology 5, 138-146.
42. Sharma S., Stolina M., Yang S., Baratelli F., Li J., Atianzar K., Luo J., Zhu L., Lin Y., Huang M., Dohadw A., Batra R. K. and Dubinett S.M. (2003). Tumor cyclooxygenase-2 dependent suppression of dendridic cell fuction. Cancer Res. 9, 961-968.
43. Smith W.L. (1992). Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 263, F181-F191
44. Specht M.C., Tucker O.N., Hocever M., Gonzales D., Teng L. and Fahey T.J. (2002). Cycooxyenase-2 expression in thyroid nodules. J. Clin. Endocrinol. Metab. 87, 358-363.
45. Spugnini E.P. and Porrello A. (2003). Potentiation of chemotherapy in companion animals with spontaneous large neoplasms by application of biphasic electric pulses. J. Exp. Clin. Cancer Res. 22, 571-580.
46. Subbaramaiah K., Telang N., Ramonetti J.T., Araki R., de Vito B., Welksler B.B. and Dannenberg A.J. (1996). Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56, 4424-4429.
47. Sutton K.M., Wright M., Fondren G., Towle C.A. and Mankin H.J. (2004). Cyclooxygenase-2 expression in chondrosarcoma. Oncology 66, 275-280.
48. Teather L.A. and Wurtman R.J. (2003). Cyclooxygenase-2 mediates platelet-activating factor-induced prostaglandin E2 release from rat primary astrocytes. Neurosc. Lett. 340, 177-180.
49. Tremblay C., Dore M., Bochsler P.N. and Sirois J. (1999). Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. J. Natl. Cancer Inst. 91, 1398-1403.
50. Vail D.M. and Mac Ewen E.G. (2000). Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 18, 781-792.
51. van der Ouderaa F.J., Buytenhek M., Slikkerveer F.J. and van Dorp D.A. (1979). On the haemoprotein character of prostaglandin endoperoxide synthetase. Biochim. Biophys. Acta 572, 29-42.
52. Vane J.R., Bakhle Y.S. and Botting R.M. (1998). Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97-120.
53. Williams C.S. and Du Bois R.N. (1996). Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol. 270, G393-G400.